Keyword: Vertex Pharmaceuticals

Kymera Therapeutics

Looking to harness the body’s protein degradation processes, Kymera has raised more than $150 million for its pipeline of small molecules, led by a program targeting IRAK4, a protein involved in disease-signaling pathways.